Equillium (EQ) Non-Current Deffered Revenue (2022 - 2023)

Equillium (EQ) reported Non-Current Deffered Revenue of $2.4 million for Q3 2023, down 59.37% quarter-over-quarter from $6.0 million in Q2 2023.

Equillium (EQ) Non-Current Deffered Revenue (2022 - 2023) Analysis & Trends

Equillium (EQ) has 2 years of Non-Current Deffered Revenue data on file, last reported at $2.4 million in Q3 2023.

Non-Current Deffered Revenue for Q3 2023 came in at $2.4 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $2.4 million (changed N/A YoY), and the FY2022 annual result was $10.4 million, changed N/A from the prior year.
Non-Current Deffered Revenue eased to $2.4 million in Q3 2023 per EQ's latest filing, from $6.0 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $10.4 million in Q4 2022 and troughed at $2.4 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Equillium	293.17 Mn	232.78 Mn	-	-

Download Data